by Peter Ciszewski | Sep 26, 2017
The American Academy of Pediatrics (AAP) welcomes efforts in the U.S. House of Representatives to reauthorize the Maternal, Infant, and Early Childhood Home Visitation (MIECHV) program during today’s consideration of a bill, the Increasing Opportunity through...
by Peter Ciszewski | Sep 25, 2017
Patients with multiple myeloma regularly receive bisphosphonates to protect their bones against lytic lesions, but a new study suggests that the novel agent denosumab could be used instead. In a head-to-head comparison with zoledronic acid in a trial involving more...
by Peter Ciszewski | Sep 25, 2017
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses treatment options for acute myelogenous leukemia (AML), which comprise a variety of chemotherapy regimens and stem cell transplantation. Current standard chemotherapy regimens cure only a minority...
by Peter Ciszewski | Sep 25, 2017
Survival outcomes in chronic myeloid leukemia (CML) treated with imatinib as monotherapy are high and are not necessarily influenced by faster responses or disease-related factors, with outcomes more associated with comorbidities and external factors, according to...
by Peter Ciszewski | Sep 25, 2017
A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular degeneration, new research shows. When the experimental drug is used in combination with...
